Updates from Syncona and our portfolio companies
A new Syncona company exploiting the wound healing ability of macrophages to stimulate organ repair following severe injury as a result of chronic disease. Syncona Partners, Ed Hodgkin and Gonzalo Garcia, discuss founding this new company.
Iraj Ali, Charlie Swanton and Karl Peggs discuss the dosing of the first melanoma patient with a cell therapy to specifically target all cancer cells. This marks a significant milestone for Achilles, delivering the first precision TIL therapy
Syncona speaks to one of Quell Therapeutics’ academic founders, Alberto Sanchez-Fueyo, about his career, the potential of T-regulatory cells and his vision for the business.
Syncona’s Chief Executive, Martin Murphy and Syncona Partner, Elisa Petris talk through the process for founding our innovative cell therapy company, Quell Therapeutics.